Annual Cash & Cash Equivalents
$374.04 M
+$133.09 M+55.24%
December 31, 2023
Summary
- As of February 7, 2025, NMRA annual cash & cash equivalents is $374.04 million, with the most recent change of +$133.09 million (+55.24%) on December 31, 2023.
- During the last 3 years, NMRA annual cash & cash equivalents has risen by +$182.06 million (+94.83%).
- NMRA annual cash & cash equivalents is now -8.60% below its all-time high of $409.25 million, reached on December 31, 2021.
Performance
NMRA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$275.71 M
+$125.04 M+82.98%
September 30, 2024
Summary
- As of February 7, 2025, NMRA quarterly cash and cash equivalents is $275.71 million, with the most recent change of +$125.04 million (+82.98%) on September 30, 2024.
- Over the past year, NMRA quarterly cash and cash equivalents has increased by +$92.79 million (+50.72%).
- NMRA quarterly cash and cash equivalents is now -37.22% below its all-time high of $439.14 million, reached on September 1, 2021.
Performance
NMRA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
NMRA Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +55.2% | +50.7% |
| 3 y3 years | +94.8% | +58.1% |
| 5 y5 years | +100.0% | +58.1% |
NMRA Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -8.6% | +55.2% | -33.1% | +83.0% |
| 5 y | 5-year | -8.6% | -100.0% | -37.2% | +83.0% |
| alltime | all time | -8.6% | -100.0% | -37.2% | +83.0% |
Neumora Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $275.71 M(+83.0%) |
| Jun 2024 | - | $150.68 M(-17.6%) |
| Mar 2024 | - | $182.93 M(-51.1%) |
| Dec 2023 | $374.04 M(+55.2%) | $374.04 M(-9.3%) |
| Sep 2023 | - | $412.28 M(+101.9%) |
| Jun 2023 | - | $204.22 M(-15.2%) |
| Dec 2022 | $240.94 M | $240.94 M(+38.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2022 | - | $174.40 M(-40.1%) |
| Mar 2022 | - | $291.18 M(-28.9%) |
| Dec 2021 | $409.25 M(+113.2%) | - |
| Dec 2021 | - | $409.25 M(-6.8%) |
| Sep 2021 | - | $439.14 M(+128.7%) |
| Dec 2020 | $191.98 M(>+9900.0%) | $191.98 M |
| Dec 2019 | $0.00 | - |
FAQ
- What is Neumora Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Neumora Therapeutics?
- What is Neumora Therapeutics annual cash & cash equivalents year-on-year change?
- What is Neumora Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Neumora Therapeutics?
- What is Neumora Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Neumora Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of NMRA is $374.04 M
What is the all time high annual cash & cash equivalents for Neumora Therapeutics?
Neumora Therapeutics all-time high annual cash & cash equivalents is $409.25 M
What is Neumora Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, NMRA annual cash & cash equivalents has changed by +$133.09 M (+55.24%)
What is Neumora Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of NMRA is $275.71 M
What is the all time high quarterly cash and cash equivalents for Neumora Therapeutics?
Neumora Therapeutics all-time high quarterly cash and cash equivalents is $439.14 M
What is Neumora Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, NMRA quarterly cash and cash equivalents has changed by +$92.79 M (+50.72%)